Anders Westanmo1, Peter Marshall2, Elzie Jones1, Kevin Burns1, Erin E Krebs3,4. 1. Department of Pharmacy, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA. 2. Department of Physical Medicine and Rehabilitation, Comprehensive Pain Center, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA. 3. Department of Medicine, Minneapolis VA Health Care System, Minneapolis, Minnesota, USA. 4. Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Abstract
OBJECTIVE: To describe processes and outcomes of a health system quality improvement initiative designed to reduce opioid-related harms. DESIGN: The initiative was a primary care population-level intervention to reduce high-dose opioid prescribing, which was locally defined as >200 morphine-equivalent mg (MED) daily. We describe the implementation process and report prescribing rates and primary care provider (PCP) attitudes and beliefs before and after implementation. SETTING: A VA health care system comprising one large, urban teaching hospital and 11 outpatient clinics in surrounding suburban and rural locations. SUBJECTS: All patients who received any prescription from the outpatient pharmacy (unique pharmacy patients) were included in the population. PCPs at the main hospital were surveyed. METHODS: Prescribing outcomes were determined from merged VA databases by examining rates of opioid dispensing within 90-day time windows before and after implementation. PCP beliefs and attitudes were evaluated with preimplementation and postimplementation surveys. RESULTS: Following implementation, the number of patients prescribed >200 MED daily decreased from 342 (0.65% of unique pharmacy patients) to 65 (0.12%). Overall, the number of unique pharmacy patients who received at least one opioid prescription within 90 days decreased from 6,942 (13.7%) on April 1, 2011 to 5,981 (11.0%) on October 1, 2014 (13.8% decrease). Most PCPs agreed it was reasonable for the medical center to set a 200 MED limit (76% at baseline and 87% at follow up). CONCLUSION: Opioid Safety Initiative implementation was associated with a substantial reduction in high-dose opioid prescribing. Factors that contributed to initiative success included leadership support and active clinical pharmacy engagement. Wiley Periodicals, Inc.
OBJECTIVE: To describe processes and outcomes of a health system quality improvement initiative designed to reduce opioid-related harms. DESIGN: The initiative was a primary care population-level intervention to reduce high-dose opioid prescribing, which was locally defined as >200 morphine-equivalent mg (MED) daily. We describe the implementation process and report prescribing rates and primary care provider (PCP) attitudes and beliefs before and after implementation. SETTING: A VA health care system comprising one large, urban teaching hospital and 11 outpatient clinics in surrounding suburban and rural locations. SUBJECTS: All patients who received any prescription from the outpatient pharmacy (unique pharmacy patients) were included in the population. PCPs at the main hospital were surveyed. METHODS: Prescribing outcomes were determined from merged VA databases by examining rates of opioid dispensing within 90-day time windows before and after implementation. PCP beliefs and attitudes were evaluated with preimplementation and postimplementation surveys. RESULTS: Following implementation, the number of patients prescribed >200 MED daily decreased from 342 (0.65% of unique pharmacy patients) to 65 (0.12%). Overall, the number of unique pharmacy patients who received at least one opioid prescription within 90 days decreased from 6,942 (13.7%) on April 1, 2011 to 5,981 (11.0%) on October 1, 2014 (13.8% decrease). Most PCPs agreed it was reasonable for the medical center to set a 200 MED limit (76% at baseline and 87% at follow up). CONCLUSION: Opioid Safety Initiative implementation was associated with a substantial reduction in high-dose opioid prescribing. Factors that contributed to initiative success included leadership support and active clinical pharmacy engagement. Wiley Periodicals, Inc.
Entities:
Keywords:
Chronic Pain; Implementation; Opioid Analgesics; Primary Care
Authors: Jane M Liebschutz; Ziming Xuan; Christopher W Shanahan; Marc LaRochelle; Julia Keosaian; Donna Beers; George Guara; Kristen O'Connor; Daniel P Alford; Victoria Parker; Roger D Weiss; Jeffrey H Samet; Julie Crosson; Phoebe A Cushman; Karen E Lasser Journal: JAMA Intern Med Date: 2017-09-01 Impact factor: 21.873
Authors: Pooja Lagisetty; Alex Smith; Derek Antoku; Suzanne Winter; Michael Smith; Mary Jannausch; Hae Mi Choe; Amy S B Bohnert; Michele Heisler Journal: Am J Health Syst Pharm Date: 2020-05-07 Impact factor: 2.637
Authors: Michael L Parchman; Robert B Penfold; Brooke Ike; David Tauben; Michael Von Korff; Mark Stephens; Kari A Stephens; Laura-Mae Baldwin Journal: Ann Fam Med Date: 2019-07 Impact factor: 5.166
Authors: Joseph W Frank; Cari Levy; Daniel D Matlock; Susan L Calcaterra; Shane R Mueller; Stephen Koester; Ingrid A Binswanger Journal: Pain Med Date: 2016-05-20 Impact factor: 3.750
Authors: Kathleen F Carlson; Tess A Gilbert; Benjamin J Morasco; Dagan Wright; Joshua Van Otterloo; Aldona Herrndorf; Lawrence J Cook Journal: Health Serv Res Date: 2018-08-07 Impact factor: 3.402
Authors: William G Elder; Niki Munk; Margaret M Love; Geza G Bruckner; Kathryn E Stewart; Kevin Pearce Journal: Pain Med Date: 2017-07-01 Impact factor: 3.750
Authors: Geetanjoli Banerjee; E Jennifer Edelman; Declan T Barry; Stephen Crystal; Kirsha S Gordon; Adam J Gordon; Julie R Gaither; Traci C Green; Robert D Kerns; Ajay Manhapra; Brent A Moore; David A Fiellin; Brandon D L Marshall Journal: Pain Date: 2019-09 Impact factor: 7.926
Authors: Jonathan Colasanti; Marlene C Lira; Debbie M Cheng; Jane M Liebschutz; Judith I Tsui; Leah S Forman; Meg Sullivan; Alexander Y Walley; Carly Bridden; Christin Root; Melissa Podolsky; Catherine Abrams; Kishna Outlaw; Catherine E Harris; Wendy S Armstrong; Jeffrey H Samet; Carlos Del Rio Journal: Clin Infect Dis Date: 2019-01-07 Impact factor: 9.079